Repeatability of allergen-induced airway inflammation

被引:49
作者
Gauvreau, GM [1 ]
Watson, RM [1 ]
Rerecich, TJ [1 ]
Baswick, E [1 ]
Inman, MD [1 ]
O'Byrne, PM [1 ]
机构
[1] McMaster Univ, Hlth Sci Ctr, Dept Med, Asthma Res Grp, Hamilton, ON L8N 3Z5, Canada
基金
英国医学研究理事会;
关键词
allergen challenge; sputum eosinophils; reproducibility; sample size; anti-inflammatory therapy;
D O I
10.1016/S0091-6749(99)70115-6
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Allergen inhalation challenge is a useful clinical model to investigate the effects of asthma therapies on allergen-induced airway responses; however, the repeatability of allergen-induced airway inflammation is not known. Objective: The purpose of this study was to investigate the repeatability of allergen-induced increases in sputum eosinophils. This information will allow the prediction of the number of subjects required in studies evaluating asthma therapies. Methods: Seventeen subjects completed 2 allergen challenges using the same dose of allergen, at least 3 weeks apart. Allergen-induced airway responses were measured for 7 hours after challenge. Differential cell counts from induced sputum were determined the day before and 7 and 24 hours after challenge; methacholine PC20 was measured the day before and 24 hours after challenge. Results: The intraclass correlation coefficient for maximum percent late fall in FEV1 was 0.32 and for the area of the late response was 0.61. The sample size predicted to be necessary to observe 50% attenuation of the maximum percent late fall in FEV1 and the late area under the curve with a power of 0.95 was 9 subjects. The intraclass correlation coefficient for percent of allergen-induced sputum eosinophils was 0.60 at 7 hours and 0.53 at 24 hours after challenge. With a randomized cross-over study design, the sample size predicted to be necessary to observe 50% attenuation of allergen-induced percent of eosinophils with a power of 0.95 was 5 subjects. Conclusion: Allergen inhalation challenge with measurements of sputum eosinophils is a noninvasive and reliable method for evaluating the anti-inflammatory effects of asthma therapies.
引用
收藏
页码:66 / 71
页数:6
相关论文
共 31 条
[11]   The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects [J].
Fahy, JV ;
Fleming, HE ;
Wong, HH ;
Liu, JT ;
Su, JQ ;
Reimann, J ;
Fick, RB ;
Boushey, HA .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1997, 155 (06) :1828-1834
[12]   PROMINENT NEUTROPHILIC INFLAMMATION IN SPUTUM FROM SUBJECTS WITH ASTHMA EXACERBATION [J].
FAHY, JV ;
KIM, KW ;
LIU, J ;
BOUSHEY, HA .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1995, 95 (04) :843-852
[13]  
FAHY JV, 1995, J ALLERGY CLIN IMMUN, V151, pA397
[14]   EFFECT OF A PLATELET-ACTIVATING-FACTOR ANTAGONIST, WEB-2086, ON ALLERGEN-INDUCED ASTHMATIC RESPONSES [J].
FREITAG, A ;
WATSON, RM ;
MATSOS, G ;
EASTWOOD, C ;
OBYRNE, PM .
THORAX, 1993, 48 (06) :594-598
[15]  
FRIGAS E, 1981, MAYO CLIN PROC, V56, P345
[16]   Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosinophils in asthmatic subjects [J].
Gauvreau, GM ;
Jordana, M ;
Watson, RM ;
Cockcroft, DW ;
OByrne, PM .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1997, 156 (06) :1738-1745
[17]   Effects of inhaled budesonide on allergen-induced airway responses and airway inflammation [J].
Gauvreau, GM ;
Doctor, J ;
Watson, RM ;
Jordana, M ;
OByrne, PM .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1996, 154 (05) :1267-1271
[18]   Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx 1005 [J].
Hamilton, AL ;
Watson, RM ;
Wyile, G ;
OByrne, M .
THORAX, 1997, 52 (04) :348-354
[19]   REPRODUCIBILITY OF ALLERGEN-INDUCED EARLY AND LATE ASTHMATIC RESPONSES [J].
INMAN, MD ;
WATSON, R ;
COCKCROFT, DW ;
WONG, BJO ;
HARGREAVE, FE ;
OBYRNE, PM .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1995, 95 (06) :1191-1195
[20]   HUMAN EOSINOPHIL MAJOR BASIC-PROTEIN IS AN ENDOGENOUS ALLOSTERIC ANTAGONIST AT THE INHIBITORY MUSCARINIC M2-RECEPTOR [J].
JACOBY, DB ;
GLEICH, GJ ;
FRYER, AD .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (04) :1314-1318